Fig. 4: Potential of CapsidCas13a as a therapeutic against AMR bacteria infections. | Nature Communications

Fig. 4: Potential of CapsidCas13a as a therapeutic against AMR bacteria infections.

From: Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria

Fig. 4

Examination of the therapeutic effect of EC-CapsidCas13a-blaIMP-1 using a Galleria mellonella infection model. Administration of EC-CapsidCas13a-blaIMP-1 (MOI 100) into G. mellonella larvae infected with R10-61 (carbapenem-resistant clinical isolates of E. coli carrying blaIMP-1) significantly improved host survival compared to controls, EC-CapsidCas13a-nontargeting (p = 0.044), and phosphate-buffered saline (PBS; p = 0.0016). The p-value between two groups infected with R10-61, and treated with EC-CapsidCas13a-nontargeting and PBS was 0.30. The p-values are calculated by log-rank test. The results are presented as the aggregate values of three independent experiments performed using ten larvae per group. Source data are available in the Source Data file.

Back to article page